. Author manuscript; available in PMC: 2015 Nov 15.

Published in final edited form as: Cancer. 2014 Jun 19;120(22):3446–3456. doi: 10.1002/cncr.28864

Table 4.

Phase II trials of MEK inhibitors across tumor types

	Tumor type
	Melanoma	Other Tumor Types
Selumetinib	NCT01143402 NCT00866177	NCT00888134 - any tumor type NCT00553332 - biliary NCT01160718 - breast NCT00780676 - breast NCT00514761 - colorectal NCT01011933 - endometrial NCT01089101- glioma NCT01752569- Kaposi's sarcoma NCT00604721 - liver NCT00372788 - NSCLC NCT01306045 - NSCLC, thymic NCT00372944 - pancreatic NCT00551070 - ovarian, peritoneum NCT00559949 - papillary thyroid NCT01843062- thyroid
Trametinib	NCT01978236 NCT01037127 NCT01328106 BRAF inhibitor + trametinib: LCCC 1128: NCT01726738 NCT01072175 NCT01972347 NCT01928940 NCT01619774 NCT01978236	NCT01827384 - any tumor type NCT01943864 - biliary NCT01553851 - oral squamous BRAF inhibitor + trametinib: NCT01723202- thyroid NCT01750918- colorectal
Pimasertib	NCT01693068	NCT01936363- ovarian
Refametinib		NCT01915589 -hepatocellular NCT01915602- hepatocellular